Please assess the completion status of the following clinical trial:

Trial Title: D-serine Augmentation of Neuroplasticity

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE1/PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~1. Age between 18 and 50~2. DSM-V diagnosis of schizophrenia or schizoaffective disorder~3. Willing to provide informed consent~4. Auditory Cognitive impairment demonstrated by:~   a .MCCB composite domain score less than or equal to 0.5 standard deviation below normal (T score less than or equal to 45) b. And at least one of the following:~  * MCCB verbal memory domain score less than or equal to 0.5 standard deviation below normal (T score less than or equal to 45)~  * Tone matching score of less than or equal to 77.7%~5. Clinically stable for 2 months (CGI less than or equal to 4)~6. Moderate or lower cognitive disorganization (PANSS P2 less than or equal to 4)~7. Medically stable for study participation~8. Willing to use qualified methods of contraception for the study duration and up to 2 months after its end~9. Fluent English speaker~10. Normal hearing~11. Visual acuity corrected to 20/30~12. An estimated Glomerular Filtration Rate (GFR) greater than or equal to 60~13. Taking an antipsychotic medication other than clozapine at a stable dose for at least 4 weeks~14. Judged clinically not to be at significant suicide or violence risk~Exclusion Criteria:~1. ECG abnormality that is clinically significant in the context of study participation in the opinion of the study cardiologist~2. Current clozapine use~3. Presence of positive history of unstable significant medical or neurological illness~4. Positive toxicology screen for any substances of abuse~5. Substance use disorder (excluding nicotine) within last 60 days~6. Pregnant women or women of child-bearing potential, who are either not surgically-sterile or for outpatients, using appropriate methods of birth control. Women of childbearing potential must have a negative serum -hCG pregnancy test at every visit.~7. Participation in study of investigational medication/device within 4 weeks~8. Subjects with suicidal ideation with intent or plan (indicated by affirmative answers to items 4 or 5 of the Suicidal Ideation section of the baseline C-SSRS) in the 6 months prior to screening or subjects who represent a significant risk of suicide in the opinion of the investigator Section

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 50 Years
- Healthy Volunteers: f

Study Arms:
- D-serine 80 mg/kg (Type: EXPERIMENTAL): None
- Placebo (Type: PLACEBO_COMPARATOR): None
- D-serine 100 mg/kg (Type: EXPERIMENTAL): None
- D-serine 120 mg/g (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).